CHU Rouen, Vascular Hemostasis Unit, F-76000 Rouen, France.
Normandie Univ, UNIROUEN, INSERM U1096, CHU Rouen, Vascular Hemostasis Unit, F-76000 Rouen, France.
Clin Chim Acta. 2021 Dec;523:348-354. doi: 10.1016/j.cca.2021.10.021. Epub 2021 Oct 17.
Factor XI (FXI) deficiency is characterized by a lack of correlation between FXI plasma levels and the occurrence of hemorrhagic events. The main objective of our study was to determine whether thrombin generation assay (TGA) could be used to assess the hemorrhagic phenotype of patients with FXI deficiency.
All patients had confirmed laboratory measurement of FXI < 50% in two plasma samples. Relevant bleeding history was evaluated by a senior physician. TGA was performed with Calibrated Automated Thrombography, in platelet poor plasma, from patients and healthy controls. The assay was performed with PPP low reagent (1 pM of human tissue factor).
Seventy-six patients with FXI deficiency were included between 2011 and 2020. Among them, eight patients had severe deficiency (FXI < 15%). Mean age was 34 years [range: 9-77]. Endogenous thrombin potential (ETP) was significantly lower in patients with FXI deficiency and bleeding (573 nM·min [225-1214]) or no bleeding (732 nM·min [222-1435]), compared to healthy controls (1184 nM·min [933-1518]). No difference was observed for ETP and peak between patients with FXI deficiency and bleeding and patients with FXI deficiency and no bleeding. No difference was observed for ETP (923 nM·min [377-1497] vs 1063 nM·min [252-2529]), peak (82 nM [28-154] vs 131 nM [20-330]) or velocity (13.7 nM/min [3.6-29.6] vs 26.5 nM/min [2.5-90]) in women with (n = 4) and without history (n = 17) of post-partum bleeding. No difference of thrombin generation was observed in pregnant women with FXI deficiency (ETP: 1395 nM·min [351-2529]; peak: 154 nM [26-330]; velocity: 29.6 nM/min [4.1-90.0]), compared to healthy controls and a control group of healthy pregnant women.
In conclusion, under our experimental condition, a non-significant decrease of thrombin generation was observed in plasma samples of patients with FXI deficiency and bleeding. Our results suggest an increase of coagulation parameters during pregnancy in women with FXI deficiency. A larger sample size or other experimental conditions are required to evaluate the use of TGA in FXI deficiency.
因子 XI(FXI)缺乏症的特点是 FXI 血浆水平与出血事件的发生之间缺乏相关性。我们研究的主要目的是确定凝血酶生成试验(TGA)是否可用于评估 FXI 缺乏症患者的出血表型。
所有患者的 FXI 实验室测量值均<2 份血浆样本中的 50%。由一名资深医生评估相关出血史。使用 Calibrated Automated Thrombography 在血小板缺乏的血浆中从患者和健康对照者中进行 TGA。该测定使用 PPP 低试剂(1pM 人组织因子)进行。
2011 年至 2020 年间共纳入 76 例 FXI 缺乏症患者。其中 8 例患者存在严重缺乏症(FXI<15%)。平均年龄为 34 岁[范围:9-77]。与健康对照组相比,FXI 缺乏症伴出血(573nM·min[225-1214])或无出血(732nM·min[222-1435])患者的内源性凝血酶潜能(ETP)明显降低。FXI 缺乏症伴出血患者与 FXI 缺乏症无出血患者的 ETP 和峰值之间无差异。在产后出血史(n=4)和无出血史(n=17)的女性中,未观察到 ETP(923nM·min[377-1497]与 1063nM·min[252-2529])、峰值(82nM[28-154]与 131nM[20-330])或速度(13.7nM/min[3.6-29.6]与 26.5nM/min[2.5-90])存在差异。与健康对照组和健康孕妇对照组相比,妊娠 FXI 缺乏症患者的凝血酶生成无差异(ETP:1395nM·min[351-2529];峰值:154nM[26-330];速度:29.6nM/min[4.1-90.0])。
总之,在我们的实验条件下,FXI 缺乏症伴出血患者的血浆样本中凝血酶生成未见明显减少。我们的结果表明,在 FXI 缺乏症女性中,妊娠期间凝血参数增加。需要更大的样本量或其他实验条件来评估 TGA 在 FXI 缺乏症中的应用。